Pfizer Inc. (NYSE:PFE) Shares Sold by Castle Wealth Management LLC

Castle Wealth Management LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,711 shares of the biopharmaceutical company’s stock after selling 1,672 shares during the quarter. Castle Wealth Management LLC’s holdings in Pfizer were worth $366,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Worth Asset Management LLC purchased a new stake in Pfizer during the first quarter valued at about $29,000. Briaud Financial Planning Inc purchased a new stake in Pfizer during the third quarter valued at about $30,000. GoalVest Advisory LLC grew its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new stake in Pfizer during the third quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Up 2.4 %

Shares of NYSE:PFE traded up $0.60 during trading on Friday, hitting $25.99. The company’s stock had a trading volume of 38,347,117 shares, compared to its average volume of 42,429,016. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37. The stock’s 50-day moving average price is $27.11 and its two-hundred day moving average price is $28.68. The company has a market capitalization of $147.17 billion, a PE ratio of 72.19, a PEG ratio of 1.15 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the firm posted $1.14 earnings per share. The company’s revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.